OnKure Therapeutics, Inc. (OKUR)
Nasdaq · Healthcare · Biotechnology
$2.63+2.73%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $107M
- 52-week range
- $2.23 – $5.38
- 52-week change
- −9.22%
- EPS (trailing)
- −$2.95
Fiscal year to Dec 2025
- Net income
- −$59.5M
- Diluted EPS
- −$4.40
- Free cash flow
- −$51.9M
From the company’s annual report on SEC EDGAR.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Headquarters: Boulder, United States · 45 employees · onkuretherapeutics.com